Hematology/Oncology

Top Story

Enzalutamide enhances PSA response, but not time to PSA progression, vs. abiraterone

June 28, 2017

CHICAGO – Enzalutamide demonstrated a greater PSA response among patients with metastatic, castration-resistant prostate cancer than abiraterone, although time to PSA progression was unchanged between the agents, according to a multicenter phase 2 crossover study presented at the ASCO Annual Meeting.

In addition, alterations in baseline pathogenic circulating tumor DNA, or ctDNA, including TP53 and BRCA2, were predictive of poor outcomes.

ACP: Supreme Court permitting parts of travel ban ‘creates uncertainty’

June 28, 2017
The June 26 Supreme Court decision to allow parts of President Trump’s travel ban on six Muslim-majority countries to take effect generates uncertainty and…
Meeting News

Enzyme activator could be ‘disease-altering’ treatment for pyruvate kinase deficiency

June 28, 2017
Enzyme activator AG-348 sustained hemoglobin increases in adults with pyruvate kinase deficiency, according to updated data from a phase 2 trial presented at the…
In the Journals PlusPerspective

Experimental targeted therapy improves survival in acute myeloid leukemia

June 28, 2017
Enasidenib, an experimental inhibitor of IDH2, nearly tripled OS compared with historical data in patients with relapsed or treatment-resistant acute myeloid leukemia…

ACP: Postponed vote confirms flaws of the Senate health care act

June 28, 2017
The Senate’s decision to postpone the vote on its Better Care Reconciliation Act confirms that the legislation is vitally flawed, according to a statement issued…
More News Headlines »
CME

Bridging the Gap from Knowledge to Practice in CRPC

This activity is supported by educational funding provided by AbbVie Inc.; Astellas Scientific and Medical Affairs, Inc. and Medivation; and Sanofi US.

The selection of therapy for patients with castration-resistant prostate cancer (CRPC) remains challenging. Review…
More »
Video
Meeting News

VIDEO: Adam Brufsky, MD, PhD, discusses results of MONARCH-2, PALOMA-1 trials

June 23, 2017
More »
Featured

CME

Combination Strategies in Melanoma Management: What’s New and What’s Next

This activity is supported by an educational grant from Genentech, Inc.

Melanoma is the sixth most common cancer in the United States and the deadliest form of skin cancer. Although it is…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement